|
COG3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.37667655053519E-14 |
| Normal-vs-Stage2 |
6.22529999994015E-07 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62803104331033E-12 |
| Stage1-vs-Stage2 |
4.791000E-01 |
| Stage1-vs-Stage3 |
1.878090E-02 |
| Stage1-vs-Stage4 |
5.436500E-03 |
| Stage2-vs-Stage3 |
4.443900E-02 |
| Stage2-vs-Stage4 |
1.961880E-02 |
| Stage3-vs-Stage4 |
5.484600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.27599999996975E-06 |
| Normal-vs-Asian |
6.77859990361185E-10 |
| Caucasian-vs-AfricanAmerican |
3.386000E-01 |
| Caucasian-vs-Asian |
3.006400E-01 |
| AfricanAmerican-vs-Asian |
8.671800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.6251444634463E-12 |
| Male-vs-Female |
2.238400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67577063336921E-12 |
| Normal-vs-Age(41-60Yrs) |
2.23154827949656E-14 |
| Normal-vs-Age(61-80Yrs) |
1.63158375698913E-12 |
| Normal-vs-Age(81-100Yrs) |
1.56146999999995E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.022800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.923440E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.942560E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.361000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.612000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.121400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.117300E-03 |
| Classical-VS-Follicular |
7.915200E-03 |
| Classical-VS-Other |
7.863600E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
3.81670000000334E-05 |
| Tall-VS-Other |
3.236800E-01 |
| Tall-VS-Normal |
1.0325074129014E-14 |
| Follicular-VS-Other |
3.017400E-01 |
| Follicular-VS-Normal |
1.58023999999868E-05 |
| Other-VS-Normal |
6.566600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.6034291630076E-13 |
| Normal-vs-N1 |
2.23154827949656E-13 |
| N0-vs-N1 |
4.322000E-02 |
|
|
